Ken Griffin Tricida, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $12.49 $5,466 - $487,647	39,043 Added 21.81%	218,039 $32,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $1.11 Million - $1.78 Million	130,524 Added 269.28%	178,996 $1.88 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $131,711 - $213,513	-18,018 Reduced 27.1%	48,472 $469,000
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $549,985 - $795,421	-74,828 Reduced 52.95%	66,490 $546,000
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $483,320 - $1.1 Million	115,351 Added 444.22%	141,318 $1.35 Million

Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $73,645 - $95,987	-20,687 Reduced 44.34%	25,967 $120,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $90,677 - $196,295	20,750 Added 80.1%	46,654 $329,000
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $896,600 - $2.82 Million	-104,743 Reduced 80.17%	25,904 $235,000
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $674,626 - $1 Million	-31,807 Reduced 19.58%	130,647 $3.59 Million
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $284,761 - $587,756	15,451 Added 10.51%	162,454 $3.57 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $878,350 - $1.3 Million	-29,674 Reduced 16.8%	147,003 $5.55 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $2.72 Million - $3.84 Million	90,977 Added 106.16%	176,677 $5.45 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $2.05 Million - $2.59 Million	65,669 Added 327.84%	85,700 $3.38 Million
Q4 2018 Feb 14, 2019	SELL	$23.57 - $32.33 $461,335 - $632,795	-19,573 Reduced 49.42%	20,031 $472,000
Q2 2018 Aug 10, 2018	BUY	$26.0 - $29.9 $1.03 Million - $1.18 Million	39,604 New	39,604 $0

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account